Best Breakthrough Abstract — Hepa Thera to Present Latest Clinical Data at EASL Annual Meeting

The interim results previously disclosed by the company at AASLD showed that the combination therapy of HT-101 and HT-102 achieved rapid clearance of HBsAg and a clearance rate of up to 90% in patients with chronic hepatitis B, demonstrating its clinical potential as a next-generation functional cure regimen for hepatitis B. These findings also preliminarily validated the differentiated value of the dual-mechanism combination strategy of "siRNA + neutralizing antibody."

• HT-101 is a GalNAc-conjugated siRNA drug candidate independently developed by the company, designed to silence HBV RNA and inhibit the sustained production of HBsAg.
• HT-102 is a neutralizing antibody targeting HBsAg, aimed at promoting the clearance of circulating HBsAg.

Through the dual mechanism of "inhibiting antigen production + accelerating antigen clearance," the combination of the two is expected to achieve rapid, deep, and sustained HBsAg reduction in patients with chronic hepatitis B, thereby creating favorable conditions for subsequent immune restoration and durable off-treatment control.

【Title】: High rate and sustained HBsAg loss achieved with HT-101 plus HT-102 combination therapy in HBeAg-negative, nucleos(t)ide analogue-suppressed patients: ongoing off-treatment results from a multicenter Ib/IIa study

【Abstract Number】: LB26-5041/LBP-012

【Session Category】: Late breaker posters

【Presentation Dates】: May 27–30, 2026

关于我们

HepaThera Biopharmaceutical Co., Ltd. was established in May 2021 as a biotechnology company focused on the development of innovative drugs in the field of liver disease therapeutics. The company's core pipeline for the functional cure of hepatitis B, HT-101 (a GalNAc-conjugated siRNA) and HT-102 (a fully human monoclonal antibody), has advanced to Phase II clinical trials and received Breakthrough Therapy Designation from the National Medical Products Administration (NMPA). The company is also actively expanding into the broader liver disease market, including NASH and liver cancer, with a strategic focus on cutting-edge technologies such as RNA interference, antibody-drug conjugates, and cell therapy. HepaThera is committed to building an innovative drug pipeline covering the entire cycle of "antiviral, anti-fibrotic, and anti-tumor" therapies, aspiring to become a platform company with significant influence in the field of liver disease treatment.

立即扫码